Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Celgene
Celgene
Celgene’s Abraxane Fails to Hit the Mark in a Phase III Pancreatic Cancer Study
BioSpace
Wed, 03/13/19 - 12:17 pm
Celgene
Abraxane
clinical trials
pancreatic cancer
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Endpoints
Tue, 03/12/19 - 07:35 pm
Bristol-Myers Squibb
Celgene
Giovanni Caforio
M&A
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Mon, 03/11/19 - 10:25 pm
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Fierce Pharma
Mon, 03/11/19 - 10:09 pm
Bristol-Myers Squibb
Celgene
M&A
It’s what Bristol-Myers execs aren’t saying that makes one key analyst wonder about a potential buyout offer, looming Opdivo data and Plan B
Endpoints
Mon, 03/11/19 - 10:07 am
Bristol-Myers Squibb
Celgene
M&A
Opdivo
Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance
CNBC
Wed, 03/6/19 - 09:53 am
Bristol-Myers Squibb
M&A
Celgene
Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M
Endpoints
Tue, 03/5/19 - 12:02 pm
Celgene
Mark Alles
Pharma CEOs
executive pay
The Bristol-Myers–Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
Barron's
Sat, 03/2/19 - 12:39 pm
M&A
Bristol-Myers Squibb
Celgene
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington
Xconomy
Wed, 02/27/19 - 07:21 pm
Bristol-Myers Squibb
Celgene
M&A
Wellington
Celgene gets fast FDA review of Revlimid combo in lymphoma
Pharmaforum
Wed, 02/27/19 - 10:49 am
Celgene
Revlimid
FDA
Roche
Rituxan
priority review
Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote
Endpoints
Thu, 02/21/19 - 12:28 pm
Jeff Smith
Starboard
M&A
Celgene
Bristol-Myers Squibb
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Yahoo/Reuters
Sat, 02/16/19 - 03:39 pm
Bristol-Myers Squibb
Celgene
M&A
Starboard
shareholders
Celgene's Revlimid defenses withstand another challenge
Biopharma Dive
Tue, 02/12/19 - 10:14 am
Celgene
Revlimid
Multiple Myeloma
Dr Reddy's
patents
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Fierce Pharma
Wed, 02/6/19 - 10:28 pm
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Bloomberg
Mon, 02/4/19 - 11:47 am
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Celgene Takes A Step Closer To Its Bristol Merger With Solid Quarter
Investors Business Daily
Sat, 02/2/19 - 12:22 pm
Celgene
earnings
Bristol-Myers yanked its Celgene bid days before deadline—and got a better price
Fierce Pharma
Fri, 02/1/19 - 10:47 pm
M&A
Bristol-Myers Squibb
Celgene
What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
Fierce Pharma
Fri, 02/1/19 - 12:18 am
M&A
Celgene
Bristol-Myers Squibb
Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech
Endpoints
Tue, 01/29/19 - 09:48 am
Celgene
epigentics
Triphase Accelerator
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »